Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Efficacy as determined by estimates of objective response rates and response duration

Time frame: Efficacy measured at least every 8 weeks while receiving study drug

Pharmacodynamics (PD) will be assessed by evaluating markers of RAS/RAF pathway activity

Time frame: PD assessed during the first 4 weeks on study

Pharmacokinetics (PK) for BMS-908662 as determined by minimum observed concentrations [Cmin].

Time frame: PK measured during first 4 weeks on study

Pharmacokinetics (PK) for BMS-908662 as determined by maximum observed concentrations [Cmax].

Time frame: PK measured during first 4 weeks on study

Pharmacokinetics (PK) for BMS-908662 as determined by time of maximum observed concentration [Tmax].

Time frame: PK measured during first 4 weeks on study

Pharmacokinetics (PK) for BMS-908662 as determined by area under the concentration-curve for one dosing interval [AUC(TAU)].

Time frame: PK measured during first 4 weeks on study

Pharmacokinetics (PK) for BMS-908662 as determined by accumulation index [AI].

Time frame: PK measured during first 4 weeks on study